Akero Therapeutics, Inc. (0K4.F)
- GlobeNewswire
Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today the closing of its previously announced upsized underwritten public offering of 8,846,154 shares of its common stock at a public offering price of $26.00 per share, which includes the exercise in full by the underwriters of their option
- GlobeNewswire
Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today the pricing of an upsized underwritten public offering of 7,692,308 shares of its common stock at a public offering price of $26.00 per share. All of the shares in the offering are being offered by Akero Therapeutics. In addition, Akero
- Zacks
Biotech Stock Roundup: BMY Surges on Drug Approval, REGN Up on Update & More
Regulatory and pipeline updates from BMY and REGN are the key highlights from the biotech sector during the past week.
